Le Lézard
Classified in: Health, Science and technology
Subject: Stock Sale/Buyback

Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)


Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Compensation Committee of the company's Board of Directors granted four employees nonqualified stock options to purchase 65,500 shares of its common stock with an exercise price of $7.07 per share, which is equal to the closing price of Kezar's common stock on December 5, 2022, the grant date of the awards. The stock options were granted as an inducement award material to the individuals entering into employment with Kezar, in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options will vest over a four-year period, with 25% of each option vesting on the first anniversary of the employee's start date, and 1/48th of the total shares vesting monthly thereafter, subject to continued employment on each vesting date. The options are subject to the terms and conditions of Kezar's 2022 Inducement Plan and the stock option agreement covering the grants.

About Kezar Life Sciences

Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing novel treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor has completed a Phase 2 clinical trial in lupus nephritis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. KZR-261 is the first anti-cancer clinical candidate from the company's platform targeting the Sec61 translocon and the protein secretion pathway. An open-label dose-escalation Phase 1 clinical trial of KZR-261 to assess safety, tolerability and preliminary tumor activity in solid tumors is underway. For more information, visit www.kezarlifesciences.com.


These press releases may also interest you

at 16:25
PLAYSTUDIOS, Inc. ("PLAYSTUDIOS" or the "Company"), the creator of the playAWARDS loyalty platform and an award-winning developer of free-to-play mobile and social games that offer real-world rewards to players, today announced that it will release...

at 16:20
Medpace Holdings, Inc. ("Medpace") today announced financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Results Revenue for the three months ended March 31, 2024 increased 17.7% to $511.0 million, compared...

at 16:20
As demand for artificial intelligence solutions surges across various...

at 16:17
From its origin as an early entrant into online mortgage origination to its evolution as a diversified bank holding company offering a wide array of services, nbkc bank recently marked its 25th anniversary with assets of more than $1 billion and the...

at 16:15
SoundHound AI, Inc. , a global leader in voice artificial intelligence, today announced that it will report its 2024 first quarter financial results on Thursday, May 9, 2024 after market close. The company will host a conference call and webcast to...

at 16:15
Serve Robotics Inc. (the "Company" or "Serve"), a leading autonomous sidewalk delivery company, today announced the closing of its underwritten public offering of 10,000,000 shares of common stock at a price to the public of $4.00 per share, for...



News published on and distributed by: